What is the recommended dosing schedule for Invega (paliperidone) long‑acting injectable, including loading and maintenance doses and any adjustments for renal impairment?

Invega (Paliperidone) Dosing

For oral Invega (paliperidone extended-release tablets), start with 6 mg once daily for schizophrenia or schizoaffective disorder in adults with normal renal function, swallowed whole without crushing or chewing, and adjust within the 3-12 mg/day range based on response. 1

Oral Formulation Dosing

Schizophrenia

• Initial dose: 6 mg once daily (no titration required)
• Dose range: 3-12 mg once daily
• Dose adjustments: Increase in 3 mg increments at intervals >4 days after clinical reassessment
• Maximum dose: 12 mg/day 1

Schizoaffective Disorder

• Recommended dose: 6 mg once daily (no initial titration)
• Dose range: 3-12 mg once daily
• Higher doses show greater efficacy but must be balanced against increased adverse effects 1

Administration

• Take with or without food
• Must swallow whole - do not chew, divide, or crush
• The tablet shell may appear in stool (this is normal and expected) 1

Renal Impairment Adjustments

Dosing must be individualized based on creatinine clearance:

Mild Renal Impairment (CrCl 50-79 mL/min)

• Initial dose: 3 mg once daily
• Maximum dose: 6 mg once daily 1

Moderate to Severe Renal Impairment (CrCl 10-49 mL/min)

• Initial dose: 1.5 mg once daily
• Maximum dose: 3 mg once daily after clinical reassessment 1

End-Stage Renal Disease (CrCl <10 mL/min)

• Not recommended - Invega has not been studied in this population 1

The strong relationship between renal function and paliperidone exposure is critical: Drug exposure increases approximately fivefold in severe renal impairment, making dose reduction essential to prevent toxicity 2. Paliperidone is substantially renally excreted, and elderly patients often have diminished renal function requiring dose adjustment 1.

Hepatic Impairment

• Mild to moderate hepatic impairment (Child-Pugh A and B): No dose adjustment required
• Severe hepatic impairment: Not studied; use with caution 1

Elderly Patients

• Normal renal function: Same dosing as younger adults
• Diminished renal function: Adjust dose according to creatinine clearance (see renal impairment section above)
• Maximum dose of 3 mg once daily for elderly with moderate to severe renal impairment (CrCl 10-49 mL/min) 1

Long-Acting Injectable (LAI) Formulation

Initiation Regimen (Paliperidone Palmitate Monthly - PP1M)

The FDA-approved loading strategy requires deltoid injections for the first two doses:

• Day 1: 234 mg (150 mg eq.) deltoid injection
• Day 8 (±2 days): 156 mg (100 mg eq.) deltoid injection
• No oral supplementation required 3, 4

Needle selection for deltoid injections:

• Weight <90 kg: 1-inch, 23-gauge needle
• Weight ≥90 kg: 1.5-inch, 22-gauge needle 3, 4

Maintenance Dosing (Monthly)

• Recommended dose: 117 mg (75 mg eq.) monthly
• Dose range: 39-234 mg (25-150 mg eq.)
• Injection site: Deltoid (weight-adjusted needle) or gluteal (1.5-inch, 22-gauge needle)
• Dosing window: ±7 days from scheduled date 3, 4

Three-Monthly Formulation (PP3M)

Only switch to PP3M after at least 4 months of stable PP1M treatment:

• First PP3M dose: 3.5-fold multiple of last PP1M dose (175-525 mg eq.)
• Give at time of next scheduled PP1M injection (±1 week window)
• Subsequent doses: Every 3 months (±2 weeks window)
• Maximum dose: 525 mg eq. 5

Switching from Other Antipsychotics

• From oral antipsychotics: Initiate LAI the day after discontinuing oral medication
• From other LAIs (including long-acting risperidone): Start paliperidone palmitate at the time of next scheduled injection of previous LAI 3, 4

Missed Doses - Critical Management

The approach depends on how long since the last injection:

For Monthly Formulation (PP1M):

• Within dosing window (+7 days): Give scheduled dose
• >6 weeks since last dose: Restart initiation regimen (234 mg then 156 mg deltoid) 3

A nontraditional approach of giving the second loading dose <3 days after the first has been studied and showed no increase in 30-day readmission or adverse events, though this is off-label 6. However, severe and prolonged Parkinsonism can occur with standard loading doses in susceptible patients 7, emphasizing the need for careful monitoring.

Special Considerations

Concomitant Use with Risperidone

Avoid combining Invega with risperidone - paliperidone is the major active metabolite of risperidone, leading to additive exposure and increased risk of adverse effects 1

Drug Interactions Affecting Renal Function

The number of medications affecting renal function (NSAIDs, ACE inhibitors/ARBs, diuretics) significantly increases paliperidone exposure 2. In patients taking multiple interacting drugs:

• Consider lower starting doses
• Monitor serum concentrations if available
• Watch closely for adverse effects

Monitoring

• Renal function: Essential before initiating and periodically during treatment, especially in elderly patients
• Adverse effects: Monitor for extrapyramidal symptoms, akathisia, and drug-induced Parkinsonism
• Dose reduction or switching to lower-risk agents may be needed for movement disorders 8

Common Pitfalls to Avoid

1. Do not crush or chew tablets - this destroys the extended-release mechanism 1
2. Do not skip renal function assessment - this is the most critical determinant of dosing 1, 2
3. Do not use standard doses in renal impairment - exposure increases dramatically 1, 2
4. Do not combine with risperidone - additive paliperidone exposure 1
5. Do not use gluteal injections for initial LAI loading doses - deltoid required for proper absorption 3, 4
6. Do not switch to PP3M before 4 months of stable PP1M - insufficient data for earlier switching 5